The Combined Effect of Vulpinic Acid and Doxorubicin in Breast Cancer MCF-7 Cells

Öz

Breast cancer is a major global health problem that imposes a significant social and economic burden on individuals and societies. Chemotherapy, a common treatment approach, often leads to resistance and unwanted side effects, especially in the advanced stages of the disease. This has led to a search for more effective and less toxic anticancer agents. Lichens, which are associations of fungi and algae, are gaining attention for their potential in cancer therapy. Lichens are rich sources of secondary metabolites with diverse biological effects, including anti-tumor properties. In this study, we summarise the combined effects of vulpinic acid (VA), a lichen acid, with doxorubicin, a chemotherapeutic drug, on breast cancer MCF-7 cells. The results of the XTT assay and subsequent Compsyn analysis showed that VA and doxorubicin (Dox), a chemotherapeutic drug, alone exhibited potent anti-proliferative effects in a dose- and time-dependent manner, and interestingly, when used in combination, they produced an antagonistic effect in the same cancer line. These results provide the first example of a study to show what effect the combination of VA and Dox will have on other breast cancer cell lines.

Anahtar Kelimeler

• Breast cancer
• vulpinic acid
• doxorubicin
• combination effect.

Etik Beyan

Etik kurul onayına gerek duyulmamaktadır.

Teşekkür

I would like to thank the 100/2000 YÖK Doctoral Project, which financially supported my doctoral thesis in the field of "Natural and Herbal Products/Cosmetics". This study is part of the doctoral thesis. I would also like to thank the Erzincan Binali Yıldırım University Basic Sciences Application and Research Center and, Medicinal Aromatic Plants Application and Research Center for all the experiments that were carried out.

Kaynakça

1. [1] Hausman, D. M. (2019). What is cancer?. Perspectives in biology and medicine, 62(4), 778-784.
2. [2] DeSantis, C. E., Ma, J., Gaudet, M. M., Newman, L. A., Miller, K. D., Goding Sauer, A., Siegel, R. L. (2019). Breast cancer statistics, 2019. CA: a cancer journal for clinicians, 69(6), 438-451.
3. [3] Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 71(3), 209-249.
4. [4] Nicoletto, R. E., & Ofner III, C. M. (2022). Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells. Cancer Chemotherapy and Pharmacology, 89(3), 285-311.
5. [5] Thorn, C. F., Oshiro, C., Marsh, S., Hernandez-Boussard, T., McLeod, H., Klein, T. E., & Altman, R. B. (2011). Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenetics and genomics, 21(7), 440.
6. [6] Epstein, J. B. (2007). Mucositis in the cancer patient and immunosuppressed host. Infectious disease clinics of North America, 21(2), 503-522.
7. [7] Temel, Y., Kucukler, S., Yıldırım, S., Caglayan, C., & Kandemir, F. M. (2020). Protective effect of chrysin on cyclophosphamide-induced hepatotoxicity and nephrotoxicity via the inhibition of oxidative stress, inflammation, and apoptosis. Naunyn-Schmiedeberg's archives of pharmacology, 393, 325-337.
8. [8] Mondal, S., Bandyopadhyay, S., K Ghosh, M., Mukhopadhyay, S., Roy, S., & Mandal, C. (2012). Natural products: promising resources for cancer drug discovery. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 12(1), 49-75.

9. [9] Baytop, T. (1999). Therapy with medicinal plants in Turkey (past and present). Publication of the istanbul University, 312, 2-3.
10. [10] Mitrović, T., Stamenković, S., Cvetković, V., Nikolić, M., Tošić, S., & Stojičić, D. (2011). Lichens as source of versatile bioactive compounds. Biologica Nyssana, 2(1), 1-6.
11. [11] Kalın, Ş. N., Altay, A., & Budak, H. (2022). Inhibition of thioredoxin reductase 1 by vulpinic acid suppresses the proliferation and migration of human breast carcinoma. Life Sciences, 310, 121093.
12. [12] Lauterwein, M., Oethinger, M., Belsner, K., Peters, T., & Marre, R. (1995). In vitro activities of the lichen secondary metabolites vulpinic acid,(+)-usnic acid, and (-)-usnic acid against aerobic and anaerobic microorganisms. Antimicrobial agents and chemotherapy, 39(11), 2541-2543.
13. [13] Demir, Y., Ceylan, H., Türkeş, C., & Beydemir, Ş. (2022). Molecular docking and inhibition studies of vulpinic, carnosic and usnic acids on polyol pathway enzymes. Journal of Biomolecular Structure and Dynamics, 40(22), 12008-12021.
14. [14] Kılıç, N., Aras, S., & Cansaran-Duman, D. (2018). Determination of vulpinic acid effect on apoptosis and mRNA expression levels in breast cancer cell lines. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 18(14), 2032-2041.
15. [15] Jin, Y. Y., Li, Y. J., Ge, D. S., Zhu, L. L., Wang, Y. Y., Luo, J., ... & Chen, Y. Q. (2021). Combination of Platycodin D with docetaxel synergistically suppressed cell growth in DU-145 by enhancing apoptosis and alleviating autophagy. European Journal of Integrative Medicine, 42, 101302.
16. [16] Shokrzadeh, M., Mortazavi, P., Moghadami, A., Khayambashi, B., & Motafeghi, F. (2021). Synergistic antiproliferative and anticancer activity of carotenoid lutein or coenzyme Q10 in combination with doxorubicin on the MCF7 cell line. Applied In Vitro Toxicology, 7(4), 167-174.
17. [17] De Logu, A., Pellerano, M. L., Sanna, A., Pusceddu, M. C., Uda, P., & Saddi, B. (2003). Comparison of the susceptibility testing of clinical isolates of Mycobacterium tuberculosis by the XTT colorimetric method and the NCCLS standards method. International journal of antimicrobial agents, 21(3), 244-250.
18. [18] Altay, A., & Budak, H. (2023). Diffractaic acid exhibits thioredoxin reductase 1 inhibition in lung cancer A549 cells.
19. [19] Sever, A. (2018). Mcf-7 hücrelerinde oksidatif hasara karşı cisplatin ile kombinasyonda resveratrolün sinerjik etkisi ve oksidatif stres indeksi (Doctoral dissertation, Anadolu University (Turkey)).
20. [20] Cansaran-Duman, D., Yangin, S., & Çolak, B. (2021). The role of vulpinic acid as a natural compound in the regulation of breast cancer-associated miRNAs. Biological Research, 54.